Improving Clinical Trial Design
Posted3 months agoActive3 months ago
syllabi.directoryResearchstory
calmpositive
Debate
20/100
Clinical TrialsMedical ResearchTrial Design
Key topics
Clinical Trials
Medical Research
Trial Design
The post shares a resource for improving clinical trial design, sparking discussion on the importance of rigorous trial methodology and potential applications.
Snapshot generated from the HN discussion
Discussion Activity
Light discussionFirst comment
1h
Peak period
4
1-2h
Avg / period
4
Key moments
- 01Story posted
Oct 8, 2025 at 12:34 PM EDT
3 months ago
Step 01 - 02First comment
Oct 8, 2025 at 1:38 PM EDT
1h after posting
Step 02 - 03Peak activity
4 comments in 1-2h
Hottest window of the conversation
Step 03 - 04Latest activity
Oct 8, 2025 at 1:57 PM EDT
3 months ago
Step 04
Generating AI Summary...
Analyzing up to 500 comments to identify key contributors and discussion patterns
ID: 45517997Type: storyLast synced: 11/17/2025, 11:10:30 AM
Want the full context?
Jump to the original sources
Read the primary article or dive into the live Hacker News thread when you're ready.
Randomized controlled trial: https://en.wikipedia.org/wiki/Randomized_controlled_trial
Glossary of experimental design: https://en.wikipedia.org/wiki/Glossary_of_experimental_desig...
> Multi-arm multi-stage (MAMS) platform trials by the MRC Clinical Trials Unit at UCL — an overview of the advantages of MAMS trials, with teaching material
Is this like multi-armed bandit which marketing runs instead of A/B sometimes?
Multi-armed bandit: https://en.wikipedia.org/wiki/Multi-armed_bandit
> Cluster randomized trials by the NIH Pragmatic Trials Collaboratory
Cluster randomized trials: https://en.wikipedia.org/wiki/Cluster-randomised_controlled_...
> Crossover trials by the Cochrane Training Handbook
Crossover study, Crossover Trial: https://en.wikipedia.org/wiki/Crossover_study
But that's a different usage of the word "Crossover" than "Crossover" as an observed process and method of adaptation and optimization?
Crossover (evolutionary algorithm) https://en.wikipedia.org/wiki/Crossover_(evolutionary_algori...
> We really could get more out of this data through international collaboration and through linked data (e.g. URIs for columns). See: "Open, and Linked, FDA data" https://github.com/FDA/openfda/issues/5#issuecomment-5392966... and "ENH: Adverse Event Count / 'Use' Count Heatmap" https://github.com/FDA/openfda/issues/49
> With sales/usage counts, we'd have a denominator with which we could calculate relative hazard.
FHIR would be useful for sharing collected clinical data - for example vitals - with patients and their other providers if they choose.
FHIR could be useful for collecting chart data from clinical trial participants.
FHIR can be represented in JSON-LD, which is Linked Data in JSON such that no XML parsing is required.
Re: FHIR JSON-LD https://news.ycombinator.com/item?id=42230270 :
> /? awesome clinical open source: https://www.google.com/search?q=awesome+clinical+open+source